Emma Espinel, NP
Family · Phoenix, AZNPI 1609483486
Payments from drug & device makers
Across 90 payments — averaging $34.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Servier Pharmaceuticals LLC$753
- Pfizer$249
- AstraZeneca$220
- Johnson & Johnson$181
- Bristol Myers Squibb$126
- Astellas Pharma US Inc$119
- plus $1K from 27 others
What the payments were for
- Consulting fees$55018%
- Food & beverage$2,27574%
- Education$2588%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Servier Pharmaceuticals LLC | 5 | $753 |
| Pfizer | 11 | $249 |
| AstraZeneca(2 entities) | 9 | $220 |
| Johnson & Johnson(2 entities) | 4 | $181 |
| Bristol Myers Squibb | 6 | $126 |
| Astellas Pharma US Inc | 2 | $119 |
| Novocure Inc. | 2 | $119 |
| Daiichi Sankyo Inc. | 4 | $116 |
| Merck | 5 | $114 |
| AVEO Pharmaceuticals, Inc. | 2 | $96 |
| Eisai Inc. | 4 | $92 |
| Coherus Oncology, Inc. | 3 | $82 |
| Sobi, Inc | 3 | $78 |
| Menarini Silicon Biosystems, Inc. | 1 | $78 |
| Novartis | 3 | $73 |
| Ipsen Biopharmaceuticals, Inc | 3 | $65 |
| Tactile Systems Technology Inc | 2 | $58 |
| Array Biopharma Inc | 3 | $53 |
| Regeneron Healthcare Solutions, Inc. | 2 | $51 |
| Springworks Therapeutics, Inc. | 2 | $49 |
| Boehringer Ingelheim | 2 | $47 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $28 |
| Stemline Therapeutics Inc. | 1 | $26 |
| AbbVie | 1 | $24 |
| Accord Healthcare, Inc. | 1 | $24 |
| Progenics Pharmaceuticals, Inc. | 1 | $24 |
| Nuvation Bio Inc. | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $22 |
| Gilead | 1 | $22 |
| Adaptive Biotechnologies Corporation | 1 | $21 |
| Incyte Corporation | 1 | $20 |
| Mirati Therapeutics, Inc. | 1 | $17 |
| Karyopharm Therapeutics Inc. | 1 | $13 |
How this compares
$3,082 in reported general payments places this provider in the 85th percentile of 4,119 family providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ondansetron Hcl | 13 | $106 |
| Pantoprazole Sodium | 16 | $77 |
Paid to pharmacies, not to this prescriber.
Other family in Phoenix
- Kimberly HallaPhoenix$332K
- Audrey StevensonPhoenix$83K
- Rebekah EdwardsPhoenix$51K
- Tirsa QuartulloPhoenix$31K
- Jessica AcostaPhoenix$30K
- Stephanie JohnstonPhoenix$25K
- Kelly MarcelloPhoenix$23K
- Judith BergmanPhoenix$22K
- Lauren BonnerPhoenix$22K
- Rita GonzalezPhoenix$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.